化疗联合DC-CTL治疗不同分期非小细胞肺癌的疗效分析

The effect of chemotherapy combined with dendritic cells-cytotoxic T lymphocytes cells in patients with non-small cell lung cancer

目的:分析化疗联合树突状细胞诱导的细胞毒性T淋巴细胞(dendritic cells and cytotoxic lymphocytes,DC-CTL)对非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的疗效及安全性。方法:收集我院2013年5月至2015年12月期间住院病理确诊为Ⅰb(具有高危因素)、Ⅱa、Ⅱb、Ⅲa、Ⅲb、Ⅳ期的NSCLC患者114例,其中接受肺癌根治术的患者分为术后化疗联合DC-CTL组20例和术后化疗组32例,未行手术患者分为化疗联合DC-CTL组23例和化疗组39例。回顾分析了114例患者的临床特点、疾病控制率(disease control rate,DCR)、中位无疾病生存期(median-disease free survival,M-DFS)、中位无进展生存期(medianprogression free survival,M-PFS)、副作用等资料。随访截止至2016年11月。结果:1年DCR:术后化疗联合DC-CTL组(75.0%)vs术后化疗组(43.8%)(P=0.044)。M-DFS:术后化疗联合DC-CTL组(19.5个月)与术后化疗组(11.5个月)相比,差异具有明显统计学意义(P=0.025 5)。化疗联合DC-CTL治疗与化疗组相比,DCR及M-PFS不具有统计学差异。DC-CTL治疗的副作用显著低于化疗。结论:术后化疗联合DC-CTL治疗可显著提高DCR及延缓NSCLC患者的疾病进展,且安全性高。

Objective：To analyze the activity and safety of the therapy that chemotherapy combined with dendritic cells and cytotoxic lymphocytes（ DC - CTL） cells in patients with non - small cell lung cancer（ NSCLC ）. Methods ： We collected 114 patients from our hospital who were pathological diagnosised Ⅰ b - Ⅳ stage non - small cell lung cancer（NSCLC） during 2013 -05 to 2015 - 12,20 cases of postoperative chemotherapy combined DC - CTL group and 32 cases of postoperative chemotherapy group,23 cases of chemotherapy combined DC - CTL group and 39 cases of chemotherapy group. Retraspectively analyse the clinical characteristics of 114 patients, including the disease con-trol rates（ DCR） ,median disease free survival（ M - DFS） , median progression free survival（ M - PFS） , side effects. Patients were followed until November 2016. Results ：1 year of DCR：Postoperative chemotherapy combine with DC - CTL group （75.0% ） vs postoperative chemotherapy group （43.8%）（P =0. 044 ） . M - DFS of postoperative chemo-therapy combined DC - CTL group（ 19. 5 months） was significantly longer than the postoperative chemotherapy group （11.5 months） （P = 0. 025 5 ） . Side effects of DC - CTL were significantly lower than chemotherapy. Conclusion： Postoperative chemotherapy combined with DC - CTL can slow disease progression of NSCLC patients and prolong dis-ease free survival safely.